Novo disappointed on high expectations with its second-quarter announcement resulting in stock price weakness. But after Lilly reported without disappointment, something unexpected happened.
Since the middle of 2022, when their GLP-1 agonists became recognized as effective treatments for obesity in addition to diabetes, the stock prices of Novo Nordisk A/S and Eli Lilly and Company have soared. Second-quarter earnings reports from both companies firstly led to some weakness for Novo, but then demonstrated that this is not a zero-sum game.
Novo was not the first instance this earnings season when a big pharmaceutical company’s growth in second-quarter sales and earnings...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
R&D managers can sometimes drive a drug’s development despite evidence of its unviability. This has recently resulted in a scramble to adjust in-progress trial protocol and post-approval cost-effectiveness concerns.
As the pharma earnings season wrapped up, it seemed like a contest to see which company's stock price dropped the most after their announcement and which made the poorest acquisition.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
